Cited by 147Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentPeptidase Inhibition and Analysis

The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.

Current and Emerging Therapies in Metastatic Pancreatic Cancer

Manji, Gulam Abbas, Olive, Kenneth P., Saenger, Yvonne M., Oberstein, Paul·2017·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-16-2319

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Targeted therapies and immunotherapy have changed the face of multiple solid malignancies, including metastatic melanoma and lung cancer, but no such therapies exist for pancreatic ductal adenocarcinoma (PDAC) despite the knowledge of key mutations and an increasing understanding of the tumor microenvironment. Until now, most clinical studies have not been biomarker driven in this highly immunosuppressive and heterogeneous cancer. Ongoing basic and translational studies are better classifying the disease in hopes of identifying critical pathways that distinguish the unique PDAC subtypes, which will lead to personalized therapies. In this review, we discuss the current treatment options for metastatic pancreatic cancer and highlight current ongoing clinical trials, which aim to target the stroma and the immune microenvironment either alone or in combination with standard chemotherapy. Identifying biomarkers and key resistance pathways and targeting these pathways in a personalized manner in combination with chemotherapy are likely to yield a more immediate and durable clinical benefit.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-2319

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer statistics, 2016
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Of the monotherapy ICBs tested, ipilimumab resulted in one delayed response (of the 27 treated), whereas none of the 14 patients treated with BMS-936559, a programmed death-ligand 1 (PD-L1)–directed IgG4 monoclonal antibody, experienced an objective response (36, 37).”
Result
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Pancreatic Cancer
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848

Show all 77 references

Research works printed but not linked: 1

Khalil, 2016, Modern immunotherapy for the treatment of advance gastrointestinal cancers, Oncology, 30, 85

Sorted by citations

Items 101–147 of 147

Recent advances in proteomic profiling of pancreatic ductal adenocarcinoma and the road ahead
Kim, H., Park, J., Wang, J. I., & Kim, Y. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1382356 · Cited by 7
Clinical Trials in Pancreatic Cancer: A Long Slog
Enzler, T., & Bates, S. E. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0453 · Cited by 7
Pancreatic Cancer
Hill, A., & Chung, V. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_6 · Cited by 7
The hallmarks of pancreatic cancer
Kane, L. E., Hackett, D., Lyons, R. G., Ryan, B. M., & Maher, S. G. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218437 · Cited by 8
Liposomal co-delivery system encapsulating celastrol and paclitaxel displays highly enhanced efficiency and low toxicity against pancreatic cancer
Xiao, L., Zhou, B., Luo, S., Deng, L., Xue, Y., Zhang, L., Du, Z., Li, P.-W., Wang, L., Tian, B., et al. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103947 · Cited by 6
SLCO4A1-AS1 mediates pancreatic cancer development via miR-4673/KIF21B axis
Zhang, J., Shen, Y., Ma, D., Li, Z., Zhang, Z., & Jin, W. (2022) · Open Medicine · doi:10.1515/med-2022-0418 · Cited by 6
Retracted
The impact of thromboprophylaxis with LMWHs on the survival of patients with pancreatic cancer
Sarantis, P., & Karamouzis, M. V. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.02.004 · Cited by 6
Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
Chen, S., Han, L., Guo, S., Tan, Z.-L., & Dai, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2252692 · Cited by 6
Nanotension Relief Agent Enhances Tissue Penetration by Reducing Solid Stress in Pancreatic Ductal Adenocarcinoma via Rho/ROCK Pathway Inhibition
Yu, F., Zhang, G., Sun, J., Zhao, Y., Qi, Y., Han, X., Ai, C., Sun, W., Duan, J., & Yu, D. (2025) · Biomaterials Research · doi:10.34133/bmr.0173 · Cited by 5
Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Li, D., Miermont, A. M., Sable, R. V., Quadri, H. S., Griner, L. A. M., Martin, S. E., Odzorig, T., De, S., Ferrer, M., Powers, A. S., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-1036 · Cited by 5
The BRD4 Inhibitor I-BET-762 Reduces HO-1 Expression in Macrophages and the Pancreas of Mice
Leal, A. S., & Liby, K. T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189985 · Cited by 5
Clinicopathological and molecular characterization of KRAS wild‐type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes
Toriyama, K., Masago, K., Shibata, N., Haneda, M., Kuwahara, T., Natsume, S., Kobayashi, S., Fujita, Y., Sasaki, E., Yamao, K., et al. (2025) · The Journal of Pathology · doi:10.1002/path.6432 · Cited by 4
KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry‐based subtyping
Rao, J., Sinn, M., Pelzer, U., Riess, H. B., Oettle, H., Demir, İ. E., Friess, H., Jäger, C., Steiger, K., & Muckenhuber, A. (2024) · The Journal of Pathology Clinical Research · doi:10.1002/2056-4538.12377 · Cited by 4
Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer
Hue, J. J., Bingmer, K. E., Sugumar, K., Markt, S. C., Rothermel, L. D., Hardacre, J. M., Ammori, J. B., Winter, J. M., & Ocuin, L. M. (2021) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2021.0003 · Cited by 4
Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study
Westphalen, C. B., Kukiolka, T., Garlipp, B., Hahn, L., Fuchs, M., Malfertheiner, P., Reiser, M., Kütting, F., Heinemann, V., Beringer, A., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-6636-7 · Cited by 4
Interferon-Induced Protein With Multiple Tetratricopeptide Repeats 3 Is Associated With Response to Chemotherapy and Recurrence but Not With Survival
Popp, M. C., Klippstein, M., Lohneis, P., Kalinski, T., Li, J., Quaas, A., Bludau, M., Wang, Z., Waldschmidt, D., Kunzmann, V., et al. (2020) · Pancreas · doi:10.1097/mpa.0000000000001691 · Cited by 4
Classification From Compressive Representations Of Data
Coppa, B., David, D., Héliot, R., & Michel, O. (2012) · HAL · doi:10.5281/zenodo.43132 · Cited by 4
EMT Contributes to Chemoresistance in Pancreatic Cancer
Chava, S., Gayatri, M. B., & Reddy, A. B. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817661-0.00003-2 · Cited by 3
Relevance of the stroma in pancreatic ductal adenocarcinoma and its challenges for translational research
van Pelt, J. F. (2017) · Journal of Cancer Treatment and Diagnosis · doi:10.29245/2578-2967/2018/1.1112 · Cited by 3
Research progress in the establishment of pancreatic cancer models and preclinical applications
Wu, W., Wen, K., & Zhong, Y. (2022) · Cancer Innovation · doi:10.1002/cai2.31 · Cited by 2
Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial
Dittrich, C., Königsberg, R., Mittlböck, M., Geissler, K. H., Hrgovcic, A. S., Pleiner-Duxneuner, J., Czejka, M. J., & Buchner, P. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0639-0 · Cited by 2
Iron Citrate (Synthesit) Supplementation During Pancreas Cancer Showed Surprising Results – Case Study
Kusnir, P. (2023) · Acta Medica Martiniana · doi:10.2478/acm-2023-0014 · Cited by 1
Treatment Response of Immunotherapy Combined with Chemotherapy for Advanced Pancreatic Cancer: A Meta-Analysis
Magashi, M. A., Cai, H., & Shaibu, Z. (2024) · International Journal of Science and Healthcare Research · doi:10.52403/ijshr.20240106 · Cited by 1
The use of protein phosphatase 2A activators in combination therapies for pancreas cancer
Allen-Petersen, B. L., & Sears, R. C. (2019) · Oncotarget · doi:10.18632/oncotarget.26772 · Cited by 1
Targeting Antioxidant Systems to Treat Pancreatic Cancer
Fazzari, F. G. T. (2018) · TSpace (University of Toronto)
Cancer Stem Cells And Tyrosine Kinase Receptors Directed Dual Targeted Nanoparticles For Pancreatic Ductal Adenocarcinoma Therapy And Imaging
Alzhrani, R. M. (2020) · Human Biology
Immunotherapy is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreas CancerPreprint
Hue, J. J., Bingmer, K. E., Sugumar, K., Markt, S. C., Rothermel, L. D., Hardacre, J. M., Ammori, J. B., Winter, J. M., & Ocuin, L. M. (2020) · Research Square · doi:10.21203/rs.3.rs-121110/v1
Faculty Opinions recommendation of Tumor microbiome diversity and composition influence pancreatic cancer outcomes.
Ruppin, E., & Sinha, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736361337.793564548
Identification of a gene set correlated with immune status in ovarian cancer by transcriptome-wide data miningPreprint
Fan, L., Lei, H., Lin, Y., Zhou, Z., Shu, G., Yan, Z., Zhang, T., & Yin, G. (2020) · doi:10.21203/rs.3.rs-17604/v1
Identification of a gene set correlated with immune status in ovarian cancer by transcriptome-wide data miningPreprint
Fan, L., Lei, H., Lin, Y., Zhang, T., Zhou, Z., Shu, G., Yan, Z., Chen, H., & Yin, G. (2020) · doi:10.21203/rs.3.rs-35960/v1
Mutant p53-driven lncRNA LINC00857 promotes pancreatic cancer metastasis through OTUB1- mediated FOXM1 deubiquitinationPreprint
Zhang, W., Qian, W., Gu, J., Gong, M., Zhang, W., Zhang, S., Zhou, C., Jiang, J., Han, L., Wu, Z., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1738401/v1
FTO deubiquitinated by USP7 influenced NEDD4 mRNA stability enhancing the chemoresistance of pancreatic cancer to gemcitabine by promoting cell proliferation and upregulating RRM1 expressionPreprint
Lin, K., Zhou, E., Zheng, Z., Zhang, S., Shi, T., Yang, C., Zhang, G., Cai, J., & Gao, W. (2022) · Research Square · doi:10.21203/rs.3.rs-1902113/v1
FES null mice demonstrate a reduction in neutrophil dependent pancreatic cancer metastatic burden
Strøbech, J. E., Giuriatti, P., Stagaard, R., Sepulveda, P. D., Nielsen, S. R., & Erler, J. T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1096499
Data from A Notch-Dependent Inflammatory Feedback Circuit between Macrophages and Cancer Cells Regulates Pancreatic Cancer Metastasis
Geng, Y., Fan, J., Chen, L., Zhang, C., Qu, C., Qian, L., Chen, K., Meng, Z., Chen, Z., & Wang, P. (2023) · doi:10.1158/0008-5472.c.6512727.v1
Data from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Li, D., Miermont, A. M., Sable, R. V., Quadri, H. S., Griner, L. A. M., Martin, S. E., Odzorig, T., De, S., Ferrer, M., Powers, A. S., et al. (2023) · doi:10.1158/1541-7786.c.6534771.v1
Data from Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling
Li, D., Miermont, A. M., Sable, R. V., Quadri, H. S., Griner, L. A. M., Martin, S. E., Odzorig, T., De, S., Ferrer, M., Powers, A. S., et al. (2023) · doi:10.1158/1541-7786.c.6534771.v2
Data from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yam, A. O. W., Bailey, J., Lin, F., Jakovija, A., Youlten, S. E., Counoupas, C., Gunzer, M., Bald, T., Woodruff, T. M., Triccas, J. A., et al. (2023) · doi:10.1158/0008-5472.c.6599657.v1
Fosfatase atípica DUSP11 regula a morte celular induzida pela gemcitabina por meio da ativação da via NF-κB em células de carcinoma pancreático
Santos, V. S. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2023.tde-08052023-143100
A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17)
Robinson, R. M., Reyes, L., Christopher, B. N., Duncan, R. M., Burge, R. A., Siegel, J. B., Nasarre, P., Wang, P., O’Bryan, J. P., Hobbs, G. A., et al. (2024) · Antibodies · doi:10.3390/antib13040101
SLFN11 Deficiency-Induced Gemcitabine Resistance Is Overcome by Agents Targeting the DNA Damage Response in Pancreatic Cancer Cells
Kim, J. H., Youn, Y., & Hwang, J. (2025) · Biocell · doi:10.32604/biocell.2025.062144
Advances in pyrimidine-like heterocyclic scaffolds: Innovative synthetic method for malic enzyme inhibition in pancreatic ductal adenocarcinoma (PDAC) - A comprehensive review
Mehta, S., Patel, I., & Patel, G. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118657
Multi-omics and network pharmacology reveal the mechanisms of Scutellaria barbata D.Don and Scleromitrion diffusum (Willd.) R.J.Wang against pancreatic cancer
Zhao, Z., Yang, Y., Zhang, L., He, X., Ding, K., Chen, Y., Huo, Y., Li, P., Ali, T., Ali, T., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-45676-x
Elaborating novel and effective treatment for pancreatic cancer
Lan, W. (2020) · theses.fr (ABES) · doi:10.70675/f34e035dzcf8bz4855z91edz547ce2ab2ebd
Coordinated immune architecture underlies durable survival in pancreatic cancerPreprint
Merali, N., Amin, S., Wu, S., Valverde-Hernandez, C., Gao, W., Chouari, T. A. M., Ragulan, C., Hari, P. S., Bagwan, I., Karanjia, N. D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.29.721612
Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges
Habib, R., Arnold, E., Obi, T., Vizeacoumar, F. J., & Ahmed, S. (2026) · Current Oncology · doi:10.3390/curroncol33080452 · Cited by 1
BindingDB Entry 50009217: Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.
BindingDB (2021) · UC San Diego · doi:10.7270/q2sq93vv
BindingDB Entry 50018180: In the Quest for Potent and Selective Malic Enzyme 3 Inhibitors for the Treatment of Pancreatic Ductal Adenocarcinoma.
BindingDB (2024) · UC San Diego · doi:10.7270/q2377dw7

Authors: Manji, G. A., Olive, K. P., Saenger, Y. M., & Oberstein, P.
Affiliations: NewYork–Presbyterian Hospital (US)
Columbia University Irving Medical Center (US)
Corresponding author: Manji, Gulam Abbas
ORCID: Manji, Gulam Abbas
Olive, Kenneth P.
Saenger, Yvonne M.
Oberstein, Paul
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2017-04-01
Volume: 23
Issue: 7
Pages: 1670-1678
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-16-2319
OpenAlex: W2605366445
Cited by: 145
References: 77
Citations by year: 2026: 5 · 2025: 6 · 2024: 9 · 2023: 19 · 2022: 19 · 2021: 12 · 2020: 26 · 2019: 23 · 2018: 12 · 2017: 13
FWCI: 2.13
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
Keywords: metastatic pancreatic cancer, pancreatic ductal adenocarcinoma, targeted therapy, immunotherapy, tumor microenvironment, biomarkers, drug resistance, personalized treatment, combination chemotherapy, clinical trials
MeSH terms: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Humans, Immunotherapy, Neoplasm Metastasis, Neoplasms, Second Primary, Carcinoma, Pancreatic Ductal, Precision Medicine, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Current and Emerging Therapies in Metastatic Pancreatic Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks